Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS -1.49% Days Payable is 125.62 as of Dec. 2025, which is 12% below its 10-year median of 143.27. The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Genetic Signatures ranks better than 68.95% on this metric.
The historical rank and industry rank for Genetic Signatures's Days Payable or its related term are showing as below:
ASX:GSS'
s Days Payable Range Over the Past 10 Years
Min: 84.4 Med: 143.27 Max: 472.05
Current: 123.06
During the past 11 years, Genetic Signatures's highest Days Payable was 472.05. The lowest was 84.40. And the median was 143.27.
ASX:GSS's Days Payable is ranked better than 68.95% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs ASX:GSS: 123.06
Genetic Signatures's Days Payable
declined
from Dec. 2024 (129.41) to Dec. 2025 (125.62).
It may suggest that Genetic Signaturesaccelerated paying its suppliers.
Genetic Signatures Days Payable Related Terms
Genetic Signatures Days Payable Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:GSS vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Genetic Signatures's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Days Payable distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Genetic Signatures's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a Days Payable of 125.62 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genetic Signatures and its competitors. This is 12% below median its historical median of 143.27. Over the past decade, Genetic Signatures' Days Payable has ranged from 84.40 to 472.05. According to the industry distribution chart, Genetic Signatures ranks #59 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 31.1%.
Is Genetic Signatures' Days Payable too high?
Genetic Signatures' current Days Payable of 125.62 is 12% below median its 10-year median of 143.27. Over the past 10 years, this metric has ranged from a low of 84.40 to a high of 472.05. The Medical Diagnostics & Research industry median Days Payable is 64.64. Genetic Signatures' value of 125.62 is 94.3% above this industry median. Based on the distribution chart, Genetic Signatures ranks #59 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Genetic Signatures' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #59 out of 190 companies for Days Payable. This puts Genetic Signatures in the upper half of its industry. The industry median Days Payable is 64.64. Genetic Signatures' value of 125.62 is 94.3% above this benchmark. Historically, Genetic Signatures' own Days Payable has ranged from 84.40 to 472.05 over the past decade. While the company's 10-year median is 143.27 vs. the industry median of 64.64, Genetic Signatures has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Signatures's current Days Payable of 125.62 is 94.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genetic Signatures and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current Days Payable is 125.62, which is 12% below median its own 10-year median of 143.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current Days Payable is 125.62, which is 12% below median its 10-year median of 143.27 and 94.3% above the Medical Diagnostics & Research industry median of 64.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Days Payable is 125.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
